Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.

Breast cancer research and treatment - 1 Jan 2013

Ma Cynthia X, Ellis Matthew J C, Petroni Gina R, Guo Zhanfang, Cai Shi-Rong, Ryan Christine E, Craig Lockhart A, Naughton Michael J, Pluard Timothy J, Brenin Christiana M, Picus Joel, Creekmore Allison N, Mwandoro Tibu, Yarde Erin R, Reed Jerry, Ebbert Mark, Bernard Philip S, Watson Mark, Doyle Laurence A, Dancey Janet, Piwnica-Worms Helen, Fracasso Paula M

Abstract excerpt

Mutations in TP53 lead to a defective G1 checkpoint and the dependence on checkpoint kinase 1 (Chk1) for G2 or S phase arrest in response to DNA damage. In preclinical studies, Chk1 inhibition resulted in enhanced cytotoxicity of several chemotherapeutic agents. The high frequency of TP53 mutatio...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Camptothecin

Share to Genes, p53

Share to Irinotecan

Share to Leukocytes, Mononuclear

Share to Staurosporine

Source

Open in PubMed Open full text

Identifiers

PMID: 23242585
DOI: 10.1007/s10549-012-2378-9
PMCID: PMC3539064

Genes

UCN
PDK1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23242585-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.PMID 23242585Read ↗

Inhibition of Chk1 by miR-320c increases oxaliplatin responsiveness in triple-negative breast cancerSemantic proximity Read ↗

Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.Semantic proximity Read ↗

Chk1 as a new therapeutic target in triple-negative breast cancerSemantic proximity Read ↗

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1Semantic proximity Read ↗

A novel camptothecin derivative, ZBH-01, exhibits superior antitumor efficacy than irinotecan by regulating the cell cycleSemantic proximity Read ↗

CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications.Semantic proximity Read ↗

p53‐dependent G1 arrest in 1st or 2nd cell cycle may protect human cancer cells from cell death after treatment with ionizing radiation and Chk1 inhibitorsSemantic proximity Read ↗

Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast CancerSemantic proximity Read ↗

NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancer.Semantic proximity Read ↗

Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.Semantic proximity Read ↗

Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancerSemantic proximity Read ↗

CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.